Definitive Healthcare (NASDAQ:DH) Releases FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.340-0.350 for the period, compared to the consensus estimate of 0.330. The company issued revenue guidance of $250.0 million-$251.0 million, compared to the consensus revenue estimate of $249.2 million. Definitive Healthcare also updated its Q4 guidance to $0.07 EPS.

Definitive Healthcare Price Performance

Definitive Healthcare stock traded down $0.07 during trading hours on Friday, hitting $4.24. 1,200,343 shares of the company traded hands, compared to its average volume of 326,752. The firm’s 50-day simple moving average is $4.36 and its two-hundred day simple moving average is $4.98. The firm has a market cap of $500.02 million, a P/E ratio of -1.22, a P/E/G ratio of 6.27 and a beta of 1.33. Definitive Healthcare has a 1-year low of $3.19 and a 1-year high of $10.62. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.27.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. downgraded Definitive Healthcare from a “neutral” rating to an “underweight” rating and cut their target price for the stock from $7.00 to $5.00 in a research report on Wednesday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a report on Friday. Robert W. Baird cut their price target on shares of Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Morgan Stanley reduced their price objective on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Finally, Stifel Nicolaus dropped their target price on shares of Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Definitive Healthcare has an average rating of “Hold” and a consensus price target of $5.81.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.